GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Roquefort Therapeutics PLC (OTCPK:ROQAF) » Definitions » PB Ratio

ROQAF (Roquefort Therapeutics) PB Ratio : 1.02 (As of Apr. 04, 2025)


View and export this data going back to 2022. Start your Free Trial

What is Roquefort Therapeutics PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2025-04-04), Roquefort Therapeutics's share price is $0.05. Roquefort Therapeutics's Book Value per Share for the quarter that ended in Jun. 2024 was $0.05. Hence, Roquefort Therapeutics's PB Ratio of today is 1.02.

The historical rank and industry rank for Roquefort Therapeutics's PB Ratio or its related term are showing as below:

ROQAF' s PB Ratio Range Over the Past 10 Years
Min: 0.36   Med: 1.01   Max: 1.98
Current: 0.44

During the past 3 years, Roquefort Therapeutics's highest PB Ratio was 1.98. The lowest was 0.36. And the median was 1.01.

ROQAF's PB Ratio is ranked better than
92.14% of 1285 companies
in the Biotechnology industry
Industry Median: 2.22 vs ROQAF: 0.44

During the past 12 months, Roquefort Therapeutics's average Book Value Per Share Growth Rate was -24.00% per year.

Back to Basics: PB Ratio


Roquefort Therapeutics PB Ratio Historical Data

The historical data trend for Roquefort Therapeutics's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Roquefort Therapeutics PB Ratio Chart

Roquefort Therapeutics Annual Data
Trend Dec21 Dec22 Dec23
PB Ratio
- - 2.22

Roquefort Therapeutics Semi-Annual Data
Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
PB Ratio Get a 7-Day Free Trial - - 1.90 2.22 1.22

Competitive Comparison of Roquefort Therapeutics's PB Ratio

For the Biotechnology subindustry, Roquefort Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Roquefort Therapeutics's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Roquefort Therapeutics's PB Ratio distribution charts can be found below:

* The bar in red indicates where Roquefort Therapeutics's PB Ratio falls into.


;
;

Roquefort Therapeutics PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Roquefort Therapeutics's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Jun. 2024)
=0.05/0.049
=1.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


Roquefort Therapeutics  (OTCPK:ROQAF) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Roquefort Therapeutics PB Ratio Related Terms

Thank you for viewing the detailed overview of Roquefort Therapeutics's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Roquefort Therapeutics Business Description

Traded in Other Exchanges
Address
85 Great Portland Street, First Floor, London, GBR, W1W 7LT
Roquefort Therapeutics PLC is engaged in pursuing opportunities to acquire medical biotechnology businesses. Its product portfolio consists of MDK Antibody, MDK Oligo, MDK mRNA, STAT-6 siRNA, and MK Cell. The principal activity of the Company is to develop pre-clinical next-generation medicines focused on hard-to-treat cancers.

Roquefort Therapeutics Headlines